Bayer's Prostate Cancer Drug Scores a Late-Stage Clinical Win

Bayer (OTC: BAYRY) announced on Thursday that its prostate cancer drug, Nubeqa, just scored a major late-stage clinical victory. The treatment, which is a relative latecomer to the prostate cancer scene in comparison to some of its rivals, showed strong results in delaying tumor growth in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

The phase 3 Aramis trial showed that patients that had taken Nubeqa alongside androgen deprivation therapy (ADT) had improved survival times in comparison to nmCRPC patients that were taking just a placebo alongside ADT. Although the complete data won't be available until later at a future medical meeting, it was confirmed that the study met both its primary and secondary endpoints of improving patient survival time.

Image source: Getty Images.

Source Fool.com